# Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

> **NCT01909934** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 50 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin

## Key facts

- **NCT ID:** NCT01909934
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-23
- **Primary completion:** 2021-05-04
- **Final completion:** 2024-08-29
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01909934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01909934, "Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01909934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*